456070.KQ
Encell Co. Ltd.
KOE · Healthcare · Biotechnology · KR
KRW 5,400.00
−3.74%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.2B | 5.3B | 7.2B | 10.5B | 7.4B |
| Cost of Revenue | 7.2B | 9.7B | 10.2B | 10.9B | 6.7B |
| Gross Profit | (3.3B) | (4.4B) | (3.0B) | (357.6M) | 667.5M |
| Operating Expenses | |||||
| R&D Expense | 9.0B | 7.7B | 6.6B | 6.1B | 5.7B |
| SG&A Expense | 6.3B | 2.2B | 1.4B | 1.2B | 1.1B |
| General & Admin Expense | 1.0B | 1.2B | 557.7M | 432.6M | 483.1M |
| Selling & Marketing Expense | 709.4M | 904.3M | 885.4M | 774.7M | 590.2M |
| Other Expenses | 4.0B | 4.8B | 4.6B | 4.1B | 3.2B |
| Total Operating Expenses | 15.5B | 14.6B | 12.7B | 11.4B | 10.0B |
| Cost and Expenses | 19.0B | 24.3B | 22.9B | 22.3B | 16.7B |
| Operating Income (EBIT) | (14.7B) | (19.1B) | (15.7B) | (11.8B) | (9.3B) |
| Non-Operating | |||||
| Interest Income | 1.5B | 1.4B | 717.0M | 594.9M | 471.2M |
| Interest Expense | 1.6B | 668.7M | 422.2M | 1.9B | 3.0B |
| Net Interest Income | (172.3M) | 769.8M | 294.8M | (1.2B) | (2.5B) |
| Other Non-Op Income/Expense | (5.7B) | 931.8M | 473.3M | 6.7B | (36.3B) |
| Non-Operating Income (excl Interest) | (1.1B) | (1.5B) | (895.5M) | (8.6B) | 33.3B |
| EBT (Pre-Tax Income) | (20.4B) | (16.9B) | (15.2B) | (5.1B) | (45.6B) |
| Income Tax Expense | (801.4M) | (801.4M) | — | — | — |
| Bottom Line | |||||
| Net Income | (19.6B) | (16.1B) | (15.2B) | (5.1B) | (45.6B) |
| Earnings from Cont. Ops | (19.6B) | (16.1B) | (15.2B) | (5.1B) | (45.6B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (19.6B) | (16.1B) | (15.2B) | (5.1B) | (45.6B) |
| Per Share | |||||
| Basic EPS | (₩1,790) | (₩1,482) | (₩1,729) | (₩818) | (₩9,548) |
| Diluted EPS | (₩1,790) | (₩1,482) | (₩1,729) | (₩818) | (₩9,548) |
| Revenue Per Share | ₩378 | ₩484 | ₩820 | ₩1,704 | ₩1,544 |
| Shares | |||||
| Basic Shares Outstanding | 11.0M | 10.9M | 8.8M | 6.2M | 4.8M |
| Diluted Shares Outstanding | 11.0M | 10.9M | 8.8M | 6.2M | 4.8M |
| Profitability Metrics | |||||
| EBITDA | (14.9B) | (14.4B) | (10.3B) | 1.1B | (39.6B) |
| D&A | 4.7B | 4.7B | 4.5B | 4.2B | 3.0B |
| EBIT | (18.4B) | (19.1B) | (14.8B) | (3.1B) | (42.6B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026